Darrick Carter | Academic Influence

Darrick Carter's AcademicInfluence.com Rankings

Darrick Carter

Computer Science

#12268

World Rank

#13085

Historical Rank

Computational Linguistics

#3081

World Rank

#3118

Historical Rank

Machine Learning

#5629

World Rank

#5704

Historical Rank

Artificial Intelligence

#6077

World Rank

#6170

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Darrick Carter's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Darrick Carter Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Darrick Carter is an American biochemist/biophysicist, inventor, and entrepreneur. He is known for developing various therapeutics and vaccines, such as saRNA COVID-19 vaccine, influenza vaccine, and tuberculosis vaccine. Currently, he is the CEO of Compliment Corporation, and PAI Life Sciences Incorporated, as well as Founder of HDT Bio Corporation. He also holds two affiliate Professorships at the University of Washington in the Schools of Medicine and in Global Health.

(See a Problem?)

Darrick Carter's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Insertional Tagging, Cloning, and Expression of the Toxoplasma gondii Hypoxanthine-Xanthine-Guanine Phosphoribosyltransferase Gene (1996) (414)
Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant (2011) (292)
Immunization with a Polyprotein Vaccine Consisting of the T-Cell Antigens Thiol-Specific Antioxidant, Leishmania major Stress-Inducible Protein 1, and Leishmania Elongation Initiation Factor Protects against Leishmaniasis (2002) (151)
An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates (2020) (137)
Optimized subunit vaccine protects against experimental leishmaniasis. (2009) (102)
Targeting TLRs Expands the Antibody Repertoire in Response to a Malaria Vaccine (2011) (98)
Mass Spectrometric Identification of Mtb81, a Novel Serological Marker for Tuberculosis (2000) (92)
Mammaglobin: a candidate diagnostic marker for breast cancer. (2004) (87)
Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. (2002) (86)
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140 (2012) (84)
Crystal structures of Toxoplasma gondii HGXPRTase reveal the catalytic role of a long flexible loop (1996) (80)
A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7 (2014) (75)
WT1-specific serum antibodies in patients with leukemia. (2001) (74)
Crystal structures of Toxoplasma gondii uracil phosphoribosyltransferase reveal the atomic basis of pyrimidine discrimination and prodrug binding (1998) (69)
Localization and Targeting of the Leishmania donovaniHypoxanthine-Guanine Phosphoribosyltransferase to the Glycosome* (1998) (66)
The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. (2016) (65)
Adjuvants for malaria vaccines (2009) (65)
A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines (2017) (63)
Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL‐18, and IFN‐γ (2015) (62)
Hypoxanthine-guanine phosphoribosyltransferase as a therapeutic target in protozoal infections. (1995) (62)
Immunological Dominance of Trypanosoma cruzi Tandem Repeat Proteins (2008) (60)
Role of adjuvants in modeling the immune response (2010) (57)
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate. (2011) (56)
Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology (2019) (56)
Development of a schistosomiasis vaccine (2016) (53)
Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs (2012) (53)
Selection of Antigens and Development of Prototype Tests for Point-of-Care Leprosy Diagnosis (2008) (50)
Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers (2011) (50)
Recombinant expression, purification, and characterization of Toxoplasma gondii adenosine kinase. (1999) (45)
Chitin Microneedles for an Easy‐to‐Use Tuberculosis Skin Test (2014) (45)
Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies (2018) (43)
Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants (2016) (42)
Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons. (2014) (42)
Detection of Mammaglobin in the Sera of Patients with Breast Cancer (2002) (42)
A structure-function approach to optimizing TLR4 ligands for human vaccines (2016) (42)
Protein nanovaccine confers robust immunity against Toxoplasma (2017) (41)
Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons. (2014) (40)
Rational Design and Evaluation of a Multiepitope Chimeric Fusion Protein with the Potential for Leprosy Diagnosis (2009) (40)
Molecular and biochemical studies on the hypoxanthine-guanine phosphoribosyltransferases of the pathogenic haemoflagellates. (1997) (40)
Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial (2018) (39)
Insight toward Early Diagnosis of Leprosy through Analysis of the Developing Antibody Responses of Mycobacterium leprae-Infected Armadillos (2010) (37)
Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses (2018) (37)
Sm‐p80‐based schistosomiasis vaccine: double‐blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission‐blocking efficacy (2018) (37)
Differential Localization of Alternatively Spliced Hypoxanthine-Xanthine-Guanine Phosphoribosyltransferase Isoforms in Toxoplasma gondii* (2005) (36)
Upregulated Expression of B-Cell Antigen Family Tandem Repeat Proteins by Leishmania Amastigotes (2010) (35)
Use of ProteinChip™ array surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to identify thymosin β-4, a differentially secreted protein from lymphoblastoid cell lines (2003) (35)
Alga-Produced Malaria Transmission-Blocking Vaccine Candidate Pfs25 Formulated with a Human Use-Compatible Potent Adjuvant Induces High-Affinity Antibodies That Block Plasmodium falciparum Infection of Mosquitoes (2015) (34)
Expression, purification, and characterization of uracil phosphoribosyltransferase from Toxoplasma gondii. (1997) (34)
Intracellular Signaling and Desmoglein 2 Shedding Triggered by Human Adenoviruses Ad3, Ad14, and Ad14P1 (2015) (34)
Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen (2014) (32)
Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. (2014) (31)
The adjuvant GLA-AF enhances human intradermal vaccine responses (2018) (31)
IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants (2016) (30)
Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen. (2016) (29)
Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon (2014) (28)
TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes (2016) (27)
Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex1 (2002) (27)
Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models. (2016) (27)
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study (2016) (26)
Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates (2020) (26)
Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses. (2013) (25)
Correlates of GLA family adjuvants' activities. (2018) (22)
Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin (2015) (22)
Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice (2016) (22)
Schistosoma mansoni antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models (2018) (18)
Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques. (2013) (18)
Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death. (2005) (18)
Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine (2019) (17)
Serum antibodies to lipophilin B detected in late stage breast cancer patients. (2003) (17)
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial. (2020) (17)
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial (2020) (16)
Protein engineering to target complement evasion in cancer (2014) (15)
A Spray-dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy. (2019) (14)
Sm-p80-based schistosomiasis vaccine mediated epistatic interactions identified potential immune signatures for vaccine efficacy in mice and baboons (2017) (13)
Clinical Adjuvant Combinations Stimulate Potent B-Cell Responses In Vitro by Activating Dermal Dendritic Cells (2013) (12)
Biased cellular locations of tandem repeat antigens in African trypanosomes. (2011) (11)
Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic (2016) (10)
Desmoglein-2 as a prognostic and biomarker in ovarian cancer (2020) (10)
Physicochemical structure of a polyacrylic acid stabilized nanoparticle alum (nanoalum) adjuvant governs TH1 differentiation of CD4+ T cells. (2020) (9)
Spectrofluorometric Study of (2-Methyl-8-quinolinolato)Zinc(II) Chelates in Absolute Ethyl Alcohol. (1964) (9)
Serological characterizations of tandem repeat proteins for detection of African trypanosome infection in cattle. (2011) (8)
Trapping succinimides in aged polypeptides by chemical reduction (1994) (8)
Current Status of Toll-Like Receptor 4 Ligand Vaccine Adjuvants (2017) (8)
Vaccine adjuvant activity of emulsified oils from species of the Pinaceae family. (2019) (8)
Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity. (2020) (8)
Recombinant Ad35 adenoviral proteins as potent modulators of human T‐cell activation (2015) (7)
Expression and purification of immunologically reactive DPPD, a recombinant Mycobacterium tuberculosis skin test antigen, using Mycobacterium smegmatis and Escherichia coli host cells. (2004) (7)
Multi-epitope proteins for improved serological detection of Trypanosoma cruzi infection and Chagas Disease. (2016) (7)
Recent Advances and Methodological Considerations on Vaccine Candidates for Human Schistosomiasis (2021) (5)
Determination of Β-isomerized aspartic acid as the corresponding alcohol (1994) (5)
Innovations in emulsion technology (2012) (5)
An Improved Manufacturing Process for a Recombinant Polyprotein Vaccine : Combating the devastating global disease of leishmaniasis with a new therapeutic and prophylactic vaccine (2008) (5)
Structure-based Design of JOC-x, a Conjugatable Tumor Tight Junction Opener to Enhance Cancer Therapy (2019) (5)
Recombinant Ad 35 adenoviral proteins as potent modulators of human T cell activation (2014) (4)
Process Development of Sj-p80: A Low-Cost Transmission-Blocking Veterinary Vaccine for Asiatic Schistosomiasis (2021) (3)
Development of a recombinant vaccine against human onchocerciasis (2021) (3)
Immunization with a tri-antigen syphilis vaccine significantly attenuates chancre development, reduces bacterial load, and inhibits dissemination of Treponema pallidum. (2022) (2)
Emulsion-based Vaccine Adjuvants (2012) (2)
Accounting for adjuvant-induced artifacts in the characterization of vaccine formulations by polyacrylamide gel electrophoresis (2017) (2)
Chemical Deglycosylation Can Induce Methylation, Succinimide Formation, and Isomerization (2001) (1)
Phosphoribosyltransferases in Toxoplasma gondii : targets for structure-based inhibitor design (1997) (1)
Translational development of a tumor junction opening technology (2021) (1)
An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21 (2022) (1)
A Phase I Clinical Trial of an HIV-1(CN54), Clade C, Trimeric Envelope Vaccine Delivered by Parenteral, Nasal and Vaginal Routes of Immunisation (2013) (1)
Explorer Recombinant Ad 35 adenoviral proteins as potent modulators of human T cell activation (2017) (0)
P763 Attenuation of syphilis infection following immunization of rabbits with a trivalent antigen cocktail (2019) (0)
Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA (2012) (0)
E-104 Design and Development of Adjuvants for HIV Vaccines (2014) (0)
Efficacy and Safety of Chemotherapeutic Drugs Coadministration of Epithelial Junction Opener JO-1 Improves the Updated (2012) (0)
HLA-A 2 Complex by Molecular Modeling of the Peptide : HER-2 / neu Protooncogene ( 369-377 ) Selected Chain Variants of the CTL Epitope Induction of Tumor-Reactive CTL by C-Side (2002) (0)
Protein nanovaccine confers robust immunity against Toxoplasma (2017) (0)
E114 Rational Design and Clinical Development of New Adjuvants (2013) (0)
Compositions for the treatment and diagnosis of ovarian cancer (2001) (0)
P754 Quantitation of cytokines in rabbits following tri-antigen vaccine cocktail immunization and T. pallidum challenge (2019) (0)
Structure-based Design of JOC-x, a Conjugatable Tumor Tight Junction Opener to Enhance Cancer Therapy (2019) (0)
Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions (2023) (0)
Exploring the protein Landscape in Ramachandran Space: IT's not Just PSI-phi (2009) (0)
Vaccine composition containing a synthetic adjuvant (2007) (0)
STRUCTURE OF THE APO URACIL PHOSPHORIBOSYLTRANSFERASE, 2 MUTANT C128V (1999) (0)
Pre-clinical development of a vaccine for human lymphatic filariasis (2022) (0)
Invited: THE ADJUVANT GLA-AF ENHANCES HUMAN FLU VACCINE RESPONSES AFTER INTRADERMAL INJECTION USING THE NANOPASS MICRONJET (2018) (0)
HYPOXANTHINE GUANINE XANTHINE (1997) (0)
Cancer Therapy : Preclinical Coadministration of Epithelial Junction Opener JO-1 Improves theEf fi cacy andSafety ofChemotherapeuticDrugs (2012) (0)
A structure-function approach to rational adjuvant design (2016) (0)
PI‐43 (2006) (0)
Translational Activities to Enable NTD Vaccines. (2016) (0)
Identification of adjuvants for γδ T cells in response to a novel M. tuberculosis vaccine antigen (2022) (0)
STRUCTURE OF THE URACIL PHOSPHORIBOSYLTRANSFERASE, MUTANT C128V, BOUND TO PRODUCT URIDINE-1-MONOPHOSPHATE (UMP) (1999) (0)
Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial (2018) (0)
Flexgrepps - Flexible Greedy peptide Pool Search: Computation of Near-Optimal Sets of degenerate polypeptides for antigenic Screening (2012) (0)
An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21 (2022) (0)
STRUCTURE OF THE URACIL PHOSPHORIBOSYLTRANSFERASE, MUTANT C128V BOUND TO THE DRUG 5-FLUOROURACIL (1999) (0)
Crithidia fasciculata: isolation, sequencing, and expression of the hypoxanthine-guanine phosphoribosyltransferase gene. (1996) (0)
Sequence‐Based Computational Approaches to Vaccine Discovery and Design (2012) (0)
Preclinical safety, pharmacokinetics, pharmacodynamics and biodistribution studies with Ad35K++ protein, a novel rituximab co‐therapeutic in mice and non‐human primates. (2016) (0)
Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology (2019) (0)
Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon (2014) (0)

This paper list is powered by the following services:

Other Resources About Darrick Carter

en.wikipedia.org

What Schools Are Affiliated With Darrick Carter?

Darrick Carter is affiliated with the following schools: